Table 3.
Frequency of allergic reaction to the different commercial presentations of l-ASP per patient and per number of administrations.
| Type of l-asparaginase | TOTAL | Allergic reactions | p-value* | |
|---|---|---|---|---|
| n | n (%) | |||
| Analysis per patient (n = 98) | ||||
| Elspar | 29 | 4 (13.8) | a | 0.0009 |
| Aginasa | 44 | 4 (9.1) | a | |
| Leuginase | 9 | 6 (66.7 %) | b | |
| Elspar and Aginasa | 10 | 0 | a | |
| Leuginase and Aginasa | 6 | 2 (33.3 %) | ab | |
| Analysis per administration (n = 1457) | ||||
| Elspar | 457 | 4 (0.87) | a | 0.0003 |
| Aginasa | 853 | 5 (0.59) | a | |
| Leuginase | 157 | 8 (5.10) | b |
Different letters represent percentages statistically different, using an adjusted standardized residual analysis.
*
p-value was calculated using χ² test.